Literature DB >> 6247665

Heparin-induced hyperkalemia: report of a case.

K R Phelps, M S Oh, H J Carroll.   

Abstract

A 77-year-old diabetic man with a creatinine clearance of 23--27 ml/min developed hyperkalemia while receiving heparin for peripheral arterial insufficiency. Discontinuation of this agent led to resolution of hyperkalemia as the plasma aldosterone concentration multiplied by sixfold. Renal insufficiency may have predisposed this patient to the development of hyperkalemia when heparin therapy suppressed aldosterone synthesis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6247665     DOI: 10.1159/000181850

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  5 in total

1.  Hospital-acquired hyperkalaemia.

Authors:  N C Bacon
Journal:  Postgrad Med J       Date:  1997-07       Impact factor: 2.401

2.  Examination of the mechanisms whereby heparin impairs aldosterone biosynthesis.

Authors:  R O'Kelly; T J McKenna
Journal:  Ir J Med Sci       Date:  1982-12       Impact factor: 1.568

3.  Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia.

Authors:  M Monreal; E Lafoz; R Salvador; J Roncales; A Navarro
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin.

Authors:  Giuseppe Gheno; Leonardo Cinetto; Carmelo Savarino; Sandro Vellar; Maurizio Carraro; Massimo Randon
Journal:  Eur J Clin Pharmacol       Date:  2003-07-08       Impact factor: 2.953

5.  Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease--a post-hoc analysis of the PARAT trial.

Authors:  Nima Melzer; Peter Bramlage; Hans-Christoph Michaelis
Journal:  BMC Res Notes       Date:  2014-12-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.